SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) January 12, 2000
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. subsidiary, IDT, Inc., in
conjunction with HemoCleanse, Inc., announced today
that they have received FDA clearance to market the
ThermoChem-HT System and related disposables. The
ThermoChem-HT System has been developed clinically at
Wake Forest University Baptist Medical Center since
1991 by Dr. Brian Loggie, a surgical oncologist, with
correlative laboratory studies performed by Ronald
Fleming, Pharm. D., an adjunct professor. It now is
offered at the Medical Center as standard-of-care for
the treatment of ovarian, gastrointestinal, and other
tumors that have spread to the lining surface
(peritoneum) of the abdomen and pelvis (peritoneal
carcinomatosis, peritoneal mesothelioma, pseudomyxoma
peritoneum).
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: January 12, 2000
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL SUBSIDIARY, IDT, RECEIVES FDA
MARKETING CLEARANCE FOR THERMOCHEM-HT SYSTEMT
Pittsburgh, PA - January 12, 2000 - Biocontrol Technology,
Inc. (OTCBB:BICO) subsidiary, IDT, Inc., in conjunction with
HemoCleanse, Inc., announced today that they have received FDA
clearance to market the ThermoChem-HT SystemT and related
disposables.
The ThermoChem-HT System and disposables will now be
available to hospitals and doctors nationwide to help standardize
a revolutionary cancer treatment. This treatment has been
developed clinically at Wake Forest University Baptist Medical
Center since 1991 by Dr. Brian Loggie, a surgical oncologist,
with correlative laboratory studies performed by Ronald Fleming,
Pharm. D., an adjunct professor. It now is offered at the
Medical Center as standard-of-care for the treatment of ovarian,
gastrointestinal, and other tumors that have spread to the lining
surface (peritoneum) of the abdomen and pelvis (peritoneal
carcinomatosis, peritoneal mesothelioma, pseudomyxoma
peritoneum).
"We are very pleased with the clinical results that have
been achieved using the combination of surgery, Intraperitoneal
Hyperthermia, and chemotherapy," said Dr. Loggie.
The intended use of the ThermoChem-HT System is to raise the
core temperature of the peritoneum to the desired targeted
temperature in the 41 C (105.8 F) to 42 C (107.6 F) range by
continuously lavaging the peritoneum with circulating sterile
solution. Heating of the peritoneum can make the area more
receptive to adjunct therapies physicians might choose, such as
chemotherapy or natural biological agents.
Glenn Keeling, CEO of IDT, stated, "The FDA clearance is a
significant step. It reinforces our belief that by standardizing
the IPH with the ThermoChem-HT System, this cancer treatment will
be available to more patients." IDT is pursuing a strategic
partnership as part of its overall marketing plan and continues
to develop additional cancer treatment protocols to be submitted
to the FDA.
In addition, IDT is in the process of submitting clinical
and technical data to a European Notified Body. This process
will lead to the awarding of the CE Mark, which signifies that
the device meets the requirements for distribution into the
European community.
In an agreement with IDT, Biocontrol Technology, Inc.,
which is an FDA approved manufacturer and an ISO 9000
manufacturing facility, is manufacturing the ThermoChem-HT System
at its Indiana, PA facility.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. IDT, Inc., a
subsidiary of Biocontrol also located in Pittsburgh, PA, holds
exclusive worldwide marketing rights to the ThermoChem-HT System
and related disposables for regional hyperthermia and the
ThermoChem System and related disposables for whole body
hyperthermia.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
